Captor Therapeutics, a biopharmaceutical company engaged in the development of drugs based on Targeted Protein Degradation (TPD), has expanded its relationship with US-based Wedbush Securities Inc. to become the exclusive strategic financial advisor to Captor Therapeutics, with the exception of licensing transactions involving the Greater China area. In possible licensing transactions with entities in the so-called 'Greater China' area, the company will be advised by MSQ Ventures, a specialist advisor focused on this market in particular.
The purpose of the Company's extension of its cooperation with Wedbush is to identify and evaluate potential strategic opportunities aimed at maximising value for the Company's shareholders. The Company assesses that the cooperation in this regard will be long-term. The new collaboration with MSQ Ventures seeks to take advantage of MSQ's established track record in healthcare deal-making in Greater China, an area covering China, Taiwan, Hong-Kong and Macau.
- We stand by our declarations - in the medium term we plan to attract an industry strategic investor. As we know, the market environment is currently challenging, so together with the investment bank Wedbush, whom we have selected as our strategic advisor, in addition to this prospect, we are starting to work on expanding Captor's international growth opportunities. Our assets are becoming increasingly attractive among potential partners, so we want to test their shareholder value with a reputable advisor. The scope of cooperation with Wedbush has been defined broadly in order to analyse all possible avenues for Captor to build shareholder value, but, given the current market conditions and Wedbush's assessment of them, we believe that a licensing/partnership deal for the Company's projects is the most likely at this point. We also believe there are significant opportunities for licensing projects within China, which is a very specialised marker so in order to increase the potential for collaboration we have also entered into an agreement with MSQ who specialises in this type of transaction in the Chinese market. - comments Dr Tom Shepherd, CEO of Captor Therapeutics.
Captor Therapeutics operates in the global biotechnology market, where significant investment in technology and product development by industry investors is the norm, and therefore its medium-term strategy includes reaching out to specialised industry investors in the biotechnology sector in addition to the company's existing shareholders.
